PRINCETON, N.J., April 26, 2011 /PRNewswire/ -- Since every woman's body is different, getting pregnant is not the same for every woman. The First Response® Digital Ovulation Test, announced today by Church & Dwight, Co. Inc, is personalizing the process and adding clarity to conception.

Researchers at Weill Cornell Medical College have shown that it is possible to immunize mammals to control fertility.

Antioxidants are sold over the counter everywhere.

SAN FRANCISCO, June 1 /PRNewswire/ -- FIRMAGON® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr.

Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP) today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.